期刊
DRUGS OF THE FUTURE
卷 41, 期 9, 页码 547-552出版社
PROUS SCIENCE, SAU-THOMSON REUTERS
DOI: 10.1358/dof.2016.041.09.2533858
关键词
Adenosine receptors; Ocular disorders; Glaucoma; Retinal neuroprotection; Uveitis
资金
- Aerie Pharmaceuticals Inc.
- Alcon Laboratories Inc.
- Allergan Inc.
- Inotek Pharmaceuticals
- Merck
- Mati Therapeutics
- Diopsys
Adenosine is an endogenous signaling molecule that regulates a wide range of physiologic and pathophysiologic functions. These functions are modulated through its interaction with four known receptors: A(1), A(2A), A(2B) and A(3). Adenosine is produced and released by virtually all cells and is ubiquitous. Selective receptor agonists and antagonists have been developed and serve as pharmacologic probes, elucidating each receptor's specific function in a given tissue or organ. Accumulating evidence suggests that adenosine generally functions as a local cytoprotective modulator. To date, a wide range of clinical applications have been identified and active research is underway in its potential use in cardiac arrhythmias, inflammation, neuroprotection, ischemic preconditioning, and more recently ocular disorders such as glaucoma, dry eye syndrome, uveitis and diabetic retinopathy among others. In recent years, research has moved beyond the bench and selective adenosine agonists are undergoing clinical trials in humans. This review will focus on the role of adenosine and its receptors in the eye and highlight pharmacologic adenosine receptor modulators currently undergoing clinical trials for ophthalmic conditions.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据